Safety Data Analyses for First-Line Pemetrexed Plus Carboplatin (Pem plus Cb) in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC)

被引：0
|
作者：
Okamoto, I. [1 ]
Schuette, W. [2 ]
Stinchcombe, T. [3 ]
Rodrigues Pereira, J. [4 ]
Liu, J. [5 ]
San Antonio, B. [6 ]
John, W. [5 ]
Chen, J. [5 ]
Zinner, R. [7 ]
机构：
[1] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 812, Japan
[2] Hosp Martha Maria, Halle, Germany
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Inst Canc Arnaldo Vieira de Carvalho, Sao Paulo, Brazil
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Madrid, Spain
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 90卷
关键词：
D O I：
10.1016/j.ijrobp.2014.08.180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
141
引用
收藏
页码：S22 / S23
页数：2
相关论文
共 50 条
  • [1] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [2] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [3] First-line chemotherapy (CT) with pemetrexed (PEM) plus cisplatin (CIS) plus bevacuzimab (BEV) followed by maintenance PEM plus BEV for advanced nonsquamous non-small cell lung cancer (NS-NSCLC): Final results of a single-arm phase II study.
    Hillerdal, Gunnar N.
    Sorensen, Jens Benn
    Hoeffken, Gert
    Favaretto, Adolfo
    Perez-Carrion, Ramon
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Bourayou, Nawel
    Santoro, Armando
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results.
    Socinski, Mark A.
    Patel, Jyoti D.
    Garon, Edward B.
    Govindan, Ramaswamy
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Liu, Jingyi
    Guba, Susan C.
    Bonomi, Philip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).
    Patel, Jyoti D.
    Garon, Edward B.
    Govindan, Ramaswamy
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Hermann, Robert C.
    Liu, Jingyi
    Guba, Susan C.
    Pennella, Eduardo J.
    Obasaju, Coleman K.
    Bonomi, Philip D.
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC)
    Ding, Lingyu
    Liu, Kejun
    Jiang, Zhelong
    Chen, Qi
    Zhou, Ningning
    Liang, Ying
    Gao, Hongfei
    Hong, Xiangchan
    Wu, Haiying
    [J]. TUMOR BIOLOGY, 2015, 36 (04) : 2491 - 2499
  • [9] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
12345